Skip to main content
Top
Published in: Supportive Care in Cancer 3/2010

01-03-2010 | Original Article

Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population

Authors: Amanda Purcell, Jennifer Fleming, Sally Bennett, Bryan Burmeister, Terry Haines

Published in: Supportive Care in Cancer | Issue 3/2010

Login to get access

Abstract

Purpose

The Multidimensional Fatigue Inventory (MFI) is a commonly used cancer-related fatigue assessment tool. Unlike other fatigue assessments, there are no published minimal clinically important difference (MCID) criteria for the MFI in cancer populations. MCID criteria determine the smallest change in scores that can be regarded as important, allowing clinicians and researchers to interpret the meaning of changes in patient’s fatigue scores. This research aims to improve the clinical utility of the MFI by establishing MCID criteria for the MFI sub-scales in a radiotherapy population.

Materials and methods

Two hundred ten patients undergoing radiotherapy were recruited to a single-centre prospective cohort study. Patients were assessed at three time points, at the start of radiotherapy, the end of radiotherapy and 6 weeks after radiotherapy completion. Assessment consisted of four clinically relevant constructs: (1) treatment impact on fatigue, (2) health-related quality of life, (3) performance status and (4) occupational productivity. These constructs were used as external or anchor-based measures to determine MCIDs for each sub-scale of the MFI.

Results

Multiple MCIDs were identified, each from a different perspective based on the constructs cited. Researchers seeking to use a generic MCID may wish to use a two-point reference for each MFI sub-scale as it was consistent across the pre- and post-radiotherapy comparison and occupational productivity anchors.

Conclusions

MCIDs validated in this study allow better interpretation of changes in MFI sub-scale scores and allow effect size calculations for determining sample size in future studies.
Literature
1.
go back to reference Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care 4:7. doi:10.1186/1472-684X-4-7 CrossRefPubMed Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC (2005) The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care 4:7. doi:10.​1186/​1472-684X-4-7 CrossRefPubMed
4.
go back to reference Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561. doi:10.1016/S0885-3924(02)00529-8 CrossRefPubMed Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE (2002) Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 24:547–561. doi:10.​1016/​S0885-3924(02)00529-8 CrossRefPubMed
7.
go back to reference Drummond M, O’Brien B, Stoddart G, Torrance G (1993) Methods for the economic evaluation of health care programmes. Oxford Medical, New York Drummond M, O’Brien B, Stoddart G, Torrance G (1993) Methods for the economic evaluation of health care programmes. Oxford Medical, New York
8.
go back to reference Ericsson A, Mannerkorpi K (2007) Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 29:1665–1670CrossRefPubMed Ericsson A, Mannerkorpi K (2007) Assessment of fatigue in patients with fibromyalgia and chronic widespread pain. Reliability and validity of the Swedish version of the MFI-20. Disabil Rehabil 29:1665–1670CrossRefPubMed
10.
go back to reference Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D et al (2008) Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 35:635–642PubMed Goligher EC, Pouchot J, Brant R, Kherani RB, Avina-Zubieta JA, Lacaille D et al (2008) Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol 35:635–642PubMed
20.
go back to reference Portney L, Watkins M (2009) Foundations of clinical research. Pearson Prentice Hall, Upper Saddle River, pp 619–658 Portney L, Watkins M (2009) Foundations of clinical research. Pearson Prentice Hall, Upper Saddle River, pp 619–658
21.
go back to reference Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S et al (2008) Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol 61:705–713CrossRefPubMed Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S et al (2008) Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. J Clin Epidemiol 61:705–713CrossRefPubMed
24.
go back to reference Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing significance of health-related quality of life changes in clinical trials. Drug Inf J 37:23–31 Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing significance of health-related quality of life changes in clinical trials. Drug Inf J 37:23–31
26.
go back to reference Smets E, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G et al (1998) Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 78:899–906PubMed Smets E, Visser MR, Willems-Groot AF, Garssen B, Oldenburger F, van Tienhoven G et al (1998) Fatigue and radiotherapy: (A) experience in patients undergoing treatment. Br J Cancer 78:899–906PubMed
27.
go back to reference Smets E, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907–912PubMed Smets E, Visser MR, Willems-Groot AF, Garssen B, Schuster-Uitterhoeve AL, de Haes JC (1998) Fatigue and radiotherapy: (B) experience in patients 9 months following treatment. Br J Cancer 78:907–912PubMed
28.
go back to reference Strauss B, Brix C, Fischer S, Leppert K, Fuller J, Roehrig B et al (2007) The influence of resilience on fatigue in cancer patients undergoing radiation therapy (RT). J Cancer Res Clin Oncol 133:511–518. doi:10.1007/s00432-007-0195-z CrossRefPubMed Strauss B, Brix C, Fischer S, Leppert K, Fuller J, Roehrig B et al (2007) The influence of resilience on fatigue in cancer patients undergoing radiation therapy (RT). J Cancer Res Clin Oncol 133:511–518. doi:10.​1007/​s00432-007-0195-z CrossRefPubMed
29.
go back to reference Turriziani A, Mattiucci GC, Montoro C, Ferro M, Maurizi F, Smaniotto D et al (2005) Radiotherapy-related fatigue: incidence and predictive factors. Rays 30:197–203PubMed Turriziani A, Mattiucci GC, Montoro C, Ferro M, Maurizi F, Smaniotto D et al (2005) Radiotherapy-related fatigue: incidence and predictive factors. Rays 30:197–203PubMed
30.
go back to reference van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 12:405–415PubMed van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care 12:405–415PubMed
Metadata
Title
Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy population
Authors
Amanda Purcell
Jennifer Fleming
Sally Bennett
Bryan Burmeister
Terry Haines
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0653-z

Other articles of this Issue 3/2010

Supportive Care in Cancer 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine